INTELLIA THERAPEUTICS INC (NTLA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NTLA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NTLA | Director | 58 | ["Executive Vice President, Finance and Administration for AbbVie","Executive Vice President and Chief Financial Officer at AbbVie","Served in financial and strategic positions at Abbott Laboratories","Board member of Parexel International Corporation and Grail, Inc.","Bachelor’s degree in finance from the University of Illinois","M.B.A. from the University of Chicago","Financial Expert","Strategy/Corporate Development"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Chase served on the audit committee throughout 2025, serving as committee chair. Mr. Chase is independent for audit committee purposes as that term is defined in the applicable rules of the SEC and Nasdaq, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Mr. Chase is an audit committee financial expert, as defined under the applicable rules of the SEC. Mr. Chase served on the compensation committee throughout 2025. Mr. Chase is independent as defined in the applicable SEC and Nasdaq rules.